This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo® (ceftaroline fosamil): A smart choice for patients when there’s no time to wait

Indicated for the treatment of community-acquired pneumonia or complicated skin and soft tissue infections in neonates, infants, children, adolescents and adults1, Zinforo is a fifth-generation cephalosporin with an extended spectrum of activity* relative to third-generation compounds.2

Zinforo mode of action

Zinforo targets key pathogens in cSSTI and CAP in paediatric patients from birth. Use of Zinforo for the treatment of cSSTI or CAP in neonates and young infants aged <2 months is supported by evidence from adequate and well-controlled studies in adults, as well as pharmacokinetic and safety data from paediatric studies1,3-6  

Learn more

Access results of Zinforo Phase III Trials

Zinforo has a safety and tolerability profile consistent with comparator therapies in clinical studies†7-12

View safety information

Treat the majority of patients with simple dosing and a flexible infusion time

Access dosing guide

Explore More

Patient Risk Factors

Identifying patients at risk of initial treatment failure is vital for appropriate selection of antimicrobial therapy as initial treatment failure increases patients’ risk of mortality in both CAP and cSSTI.**13-18

View patient risk factors

Extended Spectrum Coverage

Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI‡1,2,19,20

Learn about coverage

Antimicrobial Stewardship

Access our resources for implementation of an Antimicrobial Stewardship Programme and learn more about Pfizer initiatives to fight antimicrobial resistance.

Access resources

Footnotes
*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible strains only), Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, and Klebsiella pneumoniae.1 Efficacy has been demonstrated in cSSTI clinical studies against the following pathogens that were susceptible to Zinforo in vitro: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus dysgalactiae, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Morganella morganii.1
Zinforo is contraindicated in patients with hypersensitivity to any active substance or excipient and should not be used in patients with a history of hypersensitivity to other cephalosporin-class antibiotics or who have had an immediate and severe hypersensitivity reaction (e.g., anaphylaxis to other β-lactam antibacterial agents). Fatal hypersensitivity reactions are possible.1 Antibacterial-associated colitis and pseudomembranous colitis (Clostridium difficile) have been reported including cases that were life-threatening.1Patients with a pre-existing seizure disorder should use Zinforo with caution as seizures occurred in toxicology studies at doses higher than typical human exposures.1 DAGT (Coombs test) became positive in 11.2% of patients from five pooled pivotal studies in patients who received Zinforo every 12 hours and in 32.3% of patients who received Zinforo every 8 hours. Although no patients developed haemolytic anaemia, there remains a potential risk.1 The most common adverse reactions occurring in ≥3% of patients treated with Zinforo were diarrhoea, headache, nausea, and pruritus and were generally mild or moderate in severity.1 Comparator therapies: cSSTI, ceftriaxone; CAP, vancomycin or cefazolin, plus optional aztreonam.
**There is no experience with Zinforo in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease, patients with PORT Risk Class V, and/or CAP requiring ventilation, CAP due to MRSA, patients requiring intensive care; the available clinical data cannot substantiate efficacy against PNSP.1 There is no experience with Zinforo in the treatment of cSSTI in the following patient groups: the immunocompromised; patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1

Abbreviations
cSSTI, complicated skin and soft tissue infection; CAP, community-acquired pneumonia. 

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References​​​​​​​
  1. ZINFORO. Summary of Product Characteristics
  2. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  3. Corey GR, et al. Clin Infect Dis 2010;51:641-50
  4. Korczowski B, et al. Pediatr Infect Dis J 2016;35:e239-47
  5. Cannavino CR, et al. Pediatr Infect Dis J 2016;35:752-9
  6. File TM, et al. Clin Infect Dis 2010;51:1395-405
  7. Ramani A, et al. J Chemother 2014;26:229–34
  8. File TM, et al. Clin Infect Dis 2010;51:1395–405
  9. Lodise TP, Low DE. Drugs 2012;72:1473–93
  10. Corey G, et al. Clin Infect Dis 2010;51:641–50
  11. Santos PD, et al. J Chemother 2013;25:341–6
  12. Corrado ML. J Antimicrob Chemother 2010;65(Suppl 4):iv67–iv71
  13. Garau J, et al. Clin Microbiol Infect 2013;19:E377–E385
  14. Garau J, et al. BMC Infect Dis 2015;15:78
  15. Edelsberg J, et al. Infect Control Hosp Epidemiol 2008;29:160–9
  16. Blasi F, et al. Resp Res 2013;14:44
  17. Menéndez R, et al. Thorax 2004;59:960–5
  18. Cogo A, et al. Infect Dis Ther 2015;4:273–82
  19. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  20. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
PP-ZFO-GBR-0218. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No